Table 4 Blood eosinophil and serum periostin levels throughout the study, by intervention
Day | Eosinophils ×10^9/L | Periostin ng/ml | ||||
|---|---|---|---|---|---|---|
FF/VI Median (min,max) | Placebo Median (min,max) | Point estimate of change from baseline (FF/VI – placebo) | FF/VI Median (min,max) | Placebo Median (min,max) | Point estimate of change from baseline (FF/VI – placebo) | |
Pre-dose | 0.35 (0.20, 1.07) | 0.34 (0.18, 1.18) | – | 191.10 (109.40, 442.50) | 189.10 (99.40, 398.60) | – |
After 14 days of treatment (day 15) | 0.30 (0.18, 0.86) | 0.38 (0.17, 0.99) | −0.06 (− 0.14, 0.02) | 150.00 (84.10, 823.40) | 171.10 (87.80, 386.40) | −3.56 (−44.36, 37.24) |
Seven days after cessation of treatment (day 21) | 0.30 (0.04, 0.85) | 0.29 (0.13, 0.70) | −0.02 (− 0.1, 0.08) | 173.50 (94.90, 471.00) | 175.70 (102.10, 389.90) | −8.86 (−30.66, 12.94) |
21 days after cessation of treatment (Day 35) | 0.36 (0.17, 0.87) | 0.40 (0.21, 1.09) | −0.04 (− 0.12, 0.06) | 171.70 (100.80, 457.70) | 185.90 (113.30, 359.60) | −5.34 (−30.16, 19.46) |